Pharmacogentic Screening of Coumarine Based Oral Anticoagulant Using Next Generation Seguencer
NCT ID: NCT03180567
Last Updated: 2017-06-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
20 participants
INTERVENTIONAL
2017-06-06
2020-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Precision Medicine Platform for Novel Oral Anticoagulants
NCT04056143
Clarification of Optimal Anticoagulation Through Genetics
NCT00839657
Patient-Centered Anticoagulation Self-Monitoring in Minority Patients
NCT02776566
Pharmacogenetics of Warfarin in Puerto Ricans.
NCT01318057
A Pharmacogenetic Study of Warfarin Dosing, "The COUMA-GEN Study"
NCT00334464
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Warfarin resistant patients
Genetic Mutations
Genetic Mutations
By next generation sequencing
Control
Genetic Mutations
Genetic Mutations
By next generation sequencing
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Genetic Mutations
By next generation sequencing
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tanta University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Amr Gawaly, Consultant
Role: PRINCIPAL_INVESTIGATOR
Hematology Dept. - Tanta University
Said Hammad Abdou, Prof
Role: PRINCIPAL_INVESTIGATOR
Clinical Pathology dept.- Tanta University
Enas Abdul-Raouf, Lecturer
Role: STUDY_DIRECTOR
Biology and Genetics- Tanta University
Abdelaziz Zidane, Lecturer
Role: STUDY_CHAIR
Genetics-Damanhour University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sherief Abd-Elsalam
Cairo, Tanta, Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Prof Amr gawaly
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.